Acuvax Of Australia Begins Human Tests Of Dengue Virus Vaccine
This article was originally published in PharmAsia News
Executive Summary
Australia's Acuvax has begun Phase I trials in the United States on a vaccine to defend against the dengue virus
Australia's Acuvax has begun Phase I trials in the United States on a vaccine to defend against the dengue virus. The vaccine is designed to use replications of proteins found in the virus to guard against it. Acuvax CEO William Ardrey said the company expected to learn in the first trials whether the vaccine spurs an immune response to dengue. (Click here for more) "Dengue Vaccine Tested On Humans" - ABC News (Australia) (1/27/10) |